CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
2022 年欧洲造血细胞移植与细胞治疗：CAR-T 活性持续增长；移植活性放缓：来自 EBMT 的报告
英文原题：Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT.
查看英文原题
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2022年，689个欧洲中心报告了在41,854名患者中进行了46,143例HCT（19,011例（41.2%）异基因和27,132例（58.8%）自体）。4329名患者接受了晚期细胞治疗，其中3205例为CAR-T。另有2854名患者接受了DLI。与上一年相比的变化是CAR-T 治疗增加（+27%），异基因（-4.0%）和自体HCT（-1.7%）减少。异基因HCT的主要适应症为髓系恶性肿瘤（10,433；58.4%）、淋系恶性肿瘤（4,674；26.2%）和非恶性疾病（2572；14.4%）。自体HCT的主要适应症为淋巴瘤（7897；32.9%）、PCD（13,694；57.1%）和实体瘤（1593；6.6%）。在异基因HCT中，同胞供者使用减少-7.7%，单倍体供者减少-6.3%，无关供者减少-0.9%。总体脐血HCT减少-16.0%。异基因HCT以及程度较轻的自体HCT在淋系恶性肿瘤中的使用减少，可能反映了新治疗方式的可用性，包括小分子、双特异性抗体和CAR-T 细胞。儿童HCT活动保持稳定（+0.3%），异基因和自体HCT之间存在差异。CAR-T 的使用继续增加，累计达到9039名患者接受治疗，欧洲各国之间差异很大。经过多年的持续增长，HCT应用的增加似乎已经放缓。
展开英文摘要原文
In 2022, 46,143 HCT (19,011 (41. 2%) allogeneic and 27,132 (58. 8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 patients received advanced cellular therapies, 3205 of which were CAR-T. An additional 2854 patients received DLI. Changes compared to the previous year were an increase in CAR-T treatments (+27%) and decrease in allogeneic (-4. 0%) and autologous HCT (-1. 7%).
Main indications for allogeneic HCT were myeloid malignancies (10,433; 58. 4%), lymphoid malignancies (4,674; 26. 2%) and non-malignant disorders (2572; 14. 4%). Main indications for autologous HCT were lymphomas (7897; 32. 9%), PCD (13,694; 57. 1%) and solid tumors (1593; 6. 6%). In allogeneic HCT, use of sibling donors decreased by -7. 7%, haploidentical donors by -6. 3% and unrelated donors by -0. 9%.
Overall cord blood HCT decreased by -16. 0%. Use of allogeneic, and to a lesser degree autologous HCT, decreased for lymphoid malignancies likely reflecting availability of new treatment modalities, including small molecules, bispecific antibodies, and CAR-T cells. Pediatric HCT activity remains stable (+0.
3%) with differences between allogeneic and autologous HCT. Use of CAR-T continues to increase and reached a cumulative total of 9039 patients treated with wide differences across European countries. After many years of continuous growth, increase in application of HCT seems to have slowed down.
论文信息
- 作者
- Passweg JR、Baldomero H、Ciceri F、de la Cámara R、Glass B、Greco R、Hazenberg MD、Kalwak K
- 第一作者单位
- EBMT Activity Survey Office, Hematology Division, University Hospital, Basel, Switzerland.Switzerland
- 通讯作者单位
- EBMT Activity Survey Office, Hematology Division, University Hospital, Basel, Switzerland. helen.baldomero@usb.ch.Switzerland
- 文献类型
- 多中心研究 · 非美国政府资助研究
- 期刊
- Bone marrow transplantation2024 Jun
- 原文标识
- PubMed 38438647 · DOI 10.1038/s41409-024-02248-9